Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Link to: Pipeline-Proof of Concept
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Link to: Pipeline-Proof of Concept
Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, granted with the Orphan Drug Designation by the European Medicines Agency and the US Food and Drug Administration, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Mercedes Hurtado – Meet the Team

https://youtu.be/XD2W5vk-Nko
Read more

The future belongs to children: 3 startups that are changing their day to day

Three emerging companies promoted by Barcelona Activa offer a series of initiatives aimed at improving…
Read more

Gate2Brain’s CEO Highlighted Among 16 Women Entrepreneurs Shaping Future Technology

We are pleased to share that Meritxell Teixidó, CEO and co-founder of Gate2Brain, has been included…
Read more

Gate2Brain to Participate in the Barcelona Deep Tech Summit 2025

, ,
Gate2Brain will be participating in the Barcelona Deep Tech Summit 2025, a meeting point for companies,…
Read more

Gate2Brain at BioJapan 2025 — Enabling Innovative Brain Delivery Solutions

,
Gate2Brain showcased its cutting-edge peptide-based technology at BioJapan 2025 in Yokohama, strengthening…
Read more

Our team grows with new incorporations and new challenges

As we return from the summer break, we want to celebrate three amazing professionals who, in the past…
Read more

Clàudia Resa – Meet the Team

, , ,
https://youtu.be/A95BWdHVZ1k
Read more

Gate2Brain turns 5!

,
Last week, we came together — team members, collaborators, advisors, funding and institutional partners…
Read more

Gate2Brain obtains FDA Orphan Drug Designation for G2B-002

, ,
US FDA grants Orphan Drug Designation for G2B-002 in 2025, underscoring U.S. regulatory support for…
Read more

Gate2Brain arrives at Alhambra Venture with technology that crosses the brain barrier

,
Ninety-eight percent of drugs designed to treat neurological diseases never reach the brain. The blood-brain…
Read more
NEWS & MEDIA
1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social